Current clinical trials in amyotrophic lateral sclerosis

Area of Science:

• Neuroscience
• Neurology
• Drug Development

Background:

• Amyotrophic lateral sclerosis (ALS) involves motor neuron degeneration, with limited therapeutic options available.
• Riluzole, approved a decade ago, remains a primary treatment, highlighting the urgent need for novel therapies.
• Advances in drug discovery are expanding the pipeline of potential ALS treatments.

Purpose of the Study:

• To review clinical trial methodologies for amyotrophic lateral sclerosis.
• To systematically evaluate drugs currently in Phase I, II, and III clinical trials for ALS.
• To emphasize the scientific rationale and trial design for each investigational drug.

Main Methods:

• Literature review of clinical trial methodology in ALS.
• Systematic evaluation of drugs in active clinical development (Phase I-III).
• Analysis of scientific evidence supporting drug selection and trial design.

Main Results:

• Identification of numerous potential therapeutic agents for ALS in various trial phases.
• Assessment of the scientific basis for drug candidates.
• Evaluation of the strengths and weaknesses of current ALS clinical trial designs.

Conclusions:

• The landscape of ALS drug development is rapidly evolving with promising new agents.
• Rigorous clinical trial design and strong scientific evidence are crucial for advancing ALS therapies.
• Continued research and development are essential to address the unmet needs in ALS treatment.